GSK plc

GSK

Bullish$51.55+3.00%3D · 2026-09-17

SettledOpen GSK

Predicted move

+3.00%

Target $51.55

Actual move at settlement

+2.02%

Confirmed close $51.06

Both measured from $50.05 on 2026-09-14 · Target close 2026-09-17

Direction correct

Actual +2.02%Move error 0.98 pp95 / 100 points

How this is scored

Direction correct: 50 points. Move error of up to 0.5 / 1 / 2 / 3 / 5 percentage points earns 50 / 45 / 35 / 25 / 10 magnitude points; larger errors earn 0. A wrong direction can still earn magnitude points. A flat close matches neither direction. Points are not returns.

Thesis

GSK closed Sep 14 at $50.05 (+4.0%, vol 3.0M) after WCLC data: Jideytro (zidesamtinib) posted a 94% ORR in TKI-naive ROS1+ NSCLC (ARROS-1), and licensor Hansoh's Phase 3 ARTEMIS-008 showed Ris-Rez cut death risk 54% vs topotecan in relapsed SCLC (median OS 18.5 vs 10.3 mo; GSK holds ex-China rights). Hold consensus PT ~$58.58 (~17% gap) and low beta leave room for a 3D grind higher as oncology follow-through digests ahead of the Fed decision. Invalidation: fade under Mon low $49.61 / prior close $48.13, or broad risk-off that hits ADRs.

Chart

Full chart

Reference chart may include later prices. Settlement uses the confirmed target-date close above.

Discussion

No discussion yet. Add evidence, a question, or a different interpretation.